The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai, ...